

20 March 2021

**08:55**

### **Welcome from OWA**

Optometry WA President, Roxanne Medhora opens WAVE 2021 with a welcome address in the Plenary room, including a welcome to country.



## **Day 1 Session 1 - Retinal - 3 Presentations** 20 March 2021

Session - Therapeutics, Interactive, Imaging Modalities/Diagnostic Equipment, Retinal Disease (Other) - 120.0 mins - Plenary Room , Plus Virtual Stream

A 2hr session grouped session on the theme of Retinal featuring a 1hr Interactive Presentation by Michael Yapp & two 30 minute lectures by Bang Bui & Michael Yapp.

**09.00**

### **OCT & Fluid - Diagnosis, Aetiology & Management of Intra-retinal Fluid**

Michael Yapp

#### **Summary**

The advent of OCT has enabled a dramatic increase in the ease of detection of intra-retinal fluid as well as the ability to detect much smaller amounts than can be seen funduscopically. Once detected, optometric management of intra-retinal fluid can vary from regular monitoring through to prompt referral. This lecture will detail the causes of intra-retinal fluid that can be detected with OCT and use a case based approach to highlight the key factors in assisting with differential diagnosis and subsequent management

#### **Learning Objectives**

By the end of this lecture, participants will:

1. Have a better understanding of the differential diagnosis of intra-retinal fluid
2. Have an increased ability to interpret OCT scans with regards to intra-retinal fluid
3. Be able to appropriately manage or refer patients with intra-retinal fluid based on the current published evidence.

**Assessment:** There are 5 optional MCQS with this lecture

**09:30**

### **Assessing Retinal Blood Vessel Regulation in Retinal Disease**

Bang Bui

**Summary:** The retina and brain are the highest consumers of energy in the body. These and other compartments of the central nervous system store very little energy and are almost entirely reliant on local mechanisms to maintain enough blood to support usage. A better understanding of how blood vessels respond to changes in local pressure (classical autoregulation) and changes in metabolic demand (neurovascular coupling) helps us to understand how the failure of autoregulation might lead to retinal disease.

**Learning Objective:** To better understand the mechanisms that underlying retinal vascular autoregulation.

**Assessment:** There are no MCQS with this lecture.

**10:00**

**Differential Diagnosis of 'Pigmentary Changes' at the Macula (I)**

Michael Yapp

**This is an Interactive session.**

**Summary**

Pigmentary changes at the macula are a common finding in routine clinical examination with the aetiology varying from benign to vision threatening. This interactive workshop will allow participants to work through a case utilising a staged approach incorporating clinical assessment and multimodal imaging, in particular OCT, OCTA and Autofluorescence, to arrive at an appropriate diagnosis and management plan.

**Learning Objectives**

By the end of this lecture, participants will:

1. Have a better understanding of the role and utility of multimodal imaging in the differential diagnosis of macular pigmentary changes
2. Have an increased ability to interpret OCT, Autofluorescence and OCTA scans with regards to macular pigmentary changes
3. Have increased confidence in the management of macular pigmentary changes

**Assessment:** There are no MCQS with this presentation, however it is interactive so be prepared to be asked to discuss some questions during the 60 minutes.

Notes

**11:00**

**20 March 2021**

**Morning Tea**

**11:30**

**20 March 2021**

## **Day 1 - Session 2: Glaucoma - 1 Presentation**

Session - [Therapeutics](#), [Glaucoma](#) - 60.0 mins - Plenary Room , Plus Virtual Stream

A 1hr session grouped session on the featuring a 1hr workshop style presentation by Dr Antony Clark on Glaucoma topic.

**11:30**

### **Managing Glaucoma Suspects (T)**

[Doctor Antony Clark](#)

**Summary:** Determining if a patient has glaucoma can often be a difficult task in early disease due the inherent variability in optic nerve head morphology. This workshop will use clinical examples to emphasise the importance of clinical assessment and the utility of ancillary tests (OCT and fields) in differentiating true glaucomatous optic neuropathy from other causes of optic nerve pathology. A suggested algorithm for follow-up of glaucoma suspects and when to refer will be discussed.

#### **Learning Objectives**

1. Review the high-risk features for glaucoma and differentiate these from non-glaucomatous optic nerve changes
2. Understand the importance of ancillary tests in monitoring for glaucoma suspects for the development of glaucoma
3. Understand when it is safe to follow-up and when to refer glaucoma suspects

**Assessment:** There are 5 optional MCQS with this lecture.

**12:30**

**20 March 2021**

## **Day 1 - Session 3: Myopia Management - 2 Presentations**

Session - [Therapeutics](#), [Paediatrics / Children's Vision](#), [Myopia Management](#) - 60.0 mins - Plenary Room , Plus Virtual Stream

Two lectures on the topic of Myopia Management by Mark Koszek & Dr Antony Clark.

**12:30**

### **Controversies & Conundrums in Myopia Management**

[Mark Koszek](#)

**Summary:** Mark's talk will focus on the controversies and conundrums in myopia management, including current understanding of the mechanisms involved in myopia development; the best means of monitoring myopia progression (eg. refractive error vs axial length); the best approach to deciding which myopia treatment is best for our patients given the current evidence.

**Learning Objective:** At the completion of the lecture the delegates will have an understanding of the factors to take into consideration when recommending myopia management.

**Assessment:** There are 5 optional MCQS with this lecture.

**13:00**

## **Atropine Update - Rethinking Myopia Management with Low-dose Atropine (T)**

Doctor Antony Clark

**Summary** It has been nearly 15 years since ATOM confirmed atropine 1% is effective in slowing myopia progression and 8 years since ATOM2 reported very low-dose atropine (0.01%) was effective longer term and well tolerated. Atropine 0.01% has become “standard of care” for treating myopic progression throughout south-east Asia on the basis of this trial. The recent Low-dose Atropine for Myopia Progression (LAMP) 2-year results showed 0.05% atropine was more effective than 0.01% and well tolerated in Hong Kong children. The WA ATOM trial in Perth will add to the evidence for atropine use in children outside Asia. There is clearly no “one size fits all” solution to treating myopic progression and this talk aims to unpack the evidence and provide a practical approach to atropine prescribing for progressive myopia.

### **Key learning objective**

Understand the latest evidence on atropine for the treatment of progressive myopia.

**Assessment:** There are 5 optional MCQS with this lecture.

**13:30**

20 March 2021

## **Lunch Break**

**14:30**

20 March 2021

## **Day 1 - Session 4: Binocular/Children's Vision**

Session - Therapeutics, Paediatrics / Children's Vision, Interactive, Binocular Vision/Strabismus - 120.0 mins - Plenary Room , Plus Virtual Stream

A 2hr grouped session Binocular Vision & Children's Vision featuring a 1hr Interactive presentation by Stephen Leslie, followed by two 30 minute lectures by Antony Clark & Stephen Leslie.

**14:30**

## **The ABC's of Binocular Vision (non strabismus) for the Busy Optometrist (I)**

Stephen Leslie

**This is an Interactive Session.**

**Summary:** Providing tips and key techniques for diagnosing and treating binocular vision problems in everyday practice. It is not uncommon for optometrists to come across (adult) patients complaining of eye strain with near and computer, delays and difficulties refocusing, blurry vision end of day, yet their vision is 6/6 with no significant refractive error.

**Learning Objective:** Participants will be able to use a sequential, evidence-based protocol to assess binocular vision and accommodation function, to detect dysfunctions which require more comprehensive assessment and possible management.

**Assessment:** There will be 5 optional MCQS with this presentation in addition to questions asked for discussion during the interactive components of the 60 minute presentation.

Notes

**15:30**

**Paediatric Pearls**

Doctor Antony Clark

**Summary:** Children with acute eye problems can be challenging to assess and manage. This talk will focus on practical tips for assessment and management of common ocular presentations in children using clinical examples. Important considerations for safe medication prescribing in children will also be discussed. The sight and life-threatening ocular conditions in kids that should not be missed will be discussed.

**Learning Objectives**

1. Practical tips on how to safely assess children with common ocular presentations including red eyes, sore eyes, styes, ocular trauma and foreign bodies.
2. Understand the important considerations for safely prescribing eye drops in children
3. Understand the features of important sight or life-threatening eye conditions presenting in children

**Assessment:** There are 5 optional MCQS with this lecture.

**16:00**

**Amblyopia: Excluding Pathology, and Differential Diagnosis.**

Stephen Leslie

**Learning Objectives:** Participants will be able to use a sequential process of patient history and visual and ocular health assessment to make an evidence-based diagnosis of amblyopia, by excluding pathology and identifying and amblyogenic agent.

**Assessment:** There are 5 optional MCQS with this lecture.

**16:30**

**20 March 2021**

**Closing Remarks**

**SUNDOWNER**

Resort Pool – 16.35 – 18.35 for all onsite at hotel.